BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7814287)

  • 1. In-vitro activity of new sulphanilil fluoroquinolones against Staphylococcus aureus.
    Allemandi DA; Alovero FL; Manzo RH
    J Antimicrob Chemother; 1994 Aug; 34(2):261-5. PubMed ID: 7814287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
    Smith KR; Cobbs CG
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
    Nishijima S; Nakagawa M; Tsuboi N; Akamatsu H; Horio T; Fujita M; Kawabata S
    J Int Med Res; 1996; 24(1):12-6. PubMed ID: 8674789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
    Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
    Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C; Voss A; Milatovic D; Braveny I
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies on pyridonecarboxylic acids as antibacterial agents. XII. Synthesis and antibacterial activity of 6-chloro-1-cyclopropyl-7-(1-piperazinyl)-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid and analogues].
    Li XH; Tian ZM; Miao H; Yu LX; Guo HY
    Yao Xue Xue Bao; 1997 Nov; 32(11):844-51. PubMed ID: 11596203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.
    Maple PA; Hamilton-Miller JM; Brumfitt W
    Antimicrob Agents Chemother; 1991 Feb; 35(2):345-50. PubMed ID: 1827242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus.
    Fuchs PC
    Am J Med; 1991 Dec; 91(6A):15S-18S. PubMed ID: 1662886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.
    Al-Nawas B; Shah PM
    J Antimicrob Chemother; 1998 Jun; 41(6):655-8. PubMed ID: 9687105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of three fluoroquinolones, cefotaxime and clindamycin against staphylococci.
    Schumacher-Perdreau F; Peters G
    Zentralbl Bakteriol; 1995 Oct; 282(4):389-93. PubMed ID: 9810661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of eight fluoroquinolones against both methicillin-susceptible and -resistant Staphylococcus aureus isolated from skin infections.
    Nishijima S; Namura S; Akamatsu H; Kawai S; Asada Y; Kawabata S; Fujita M
    J Dermatol; 1995 Feb; 22(2):153-5. PubMed ID: 7722093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin.
    Brumfitt W; Hamilton-Miller JM
    J Antimicrob Chemother; 1993 Apr; 31(4):610-2. PubMed ID: 8390435
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus.
    Aeschlimann JR; Dresser LD; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 1999 Feb; 43(2):335-40. PubMed ID: 9925528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolone resistance among methicillin-resistant staphylococci after usage of fluoroquinolones other than ciprofloxacin in Taiwan.
    Chang SC; Hsieh WC; Luh KT
    Diagn Microbiol Infect Dis; 1994 Jul; 19(3):143-7. PubMed ID: 7820993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
    Okuda J; Okamoto S; Takahata M; Nishino T
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
    Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.
    Zhao X; Eisner W; Perl-Rosenthal N; Kreiswirth B; Drlica K
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1023-7. PubMed ID: 12604537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.
    Barry AL; Fuchs PC
    J Antimicrob Chemother; 1991 Nov; 28(5):695-9. PubMed ID: 1663929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.